5 Best Biotech Stocks To Buy For 2017

Heres a roundup of everything we covered on Barrons Stocks to Watch today:

Agence France-Presse/Getty Images

We observed the market’s second triple high in less than a week and wondered what it would take for a melt up.

We offered two bullish takes on biotech stocks, one a technical argument, the other fundamental.

We explained why Mizuho upgraded Valeant Pharmaceuticals International (VRX), why B.Riley upgraded Procter & Gamble (PG), and why JPMorgan sees more upside for U.S. Steel (X).

We contemplated Under Armour’s (UA) “enormous opportunity,” McDonald’s (MCD) sluggish sales, and the distance you can drive a Tesla Motors’ (TSLA) car.

We explained how bank stocks are riskier this year than they have been in a while, how Delta Air Lines’ (DAL) cancellations last week will hit its bottom line, and why Alphabet’s (GOOG) concerns about the cost of Google fiber is not necessarily bad news for Dycom (DY).

5 Best Biotech Stocks To Buy For 2017: Amgen Inc.(AMGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Well, it looks like Medivation (MDVN) now has five suitors after reports that Amgen (AMGN) is joining Pfizer (PFE), Sanofi (SNY), AstraZeneca (AZN) and Novartis (NVS) in considering a bid. Maxim’s Jason Kolbert and Jason McCarthy offer their thoughts:

  • [By Ben Levisohn]

    After Gilead Sciences (GILD) and Amgen (AMGN) left investors wanting more, it might have been fair to wonder if Celgene (CELG) would meet the same fate when it released earnings this morning. It didn’t. And unlike Gilead and Amgen, whose shares dropped after their earnings release, Celgene is gaining.

  • [By Ben Levisohn]

    BMO Capital Markets analyst M. IanSomaiya and team take a look at the “clinical readouts through the end of 2016″ and find upside catalysts for Celgene (CELG), Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) They explain:

5 Best Biotech Stocks To Buy For 2017: ARIAD Pharmaceuticals Inc.(ARIA)

Advisors’ Opinion:

  • [By Lisa Levin] Related CXW Trump Or Clinton: Who Would Create More Jobs? The 2016 Economics Nobel Prize Winner's Case Against Private Prisons: Contracts Are The Key Wall Street Breakfast: Trump Takes The White House (Seeking Alpha) Related SAEX 20 Biggest Mid-Day Losers For Friday 22 Stocks Moving In Friday's Pre-Market Session SAExploration wins $35M seismic data deal (Seeking Alpha)
    Gainers Corrections Corp Of America (NYSE: CXW) shares rose 16.3 percent to $16.50 in pre-market trading following Donald Trump's victory. SAExploration Holdings, Inc. (NASDAQ: SAEX) shares rose 15.4 percent to $7.26 in pre-market trading after the company reported a new $35 million deep water ocean-bottom marine project award. The GEO Group Inc (NYSE: GEO) shares rose 12.9 percent to $26.95 in pre-market trading following Donald Trump's victory. Cloud Peak Energy Inc. (NYSE: CLD) rose 12.3 percent to $7.40 in pre-market trading after gaining 0.30 percent on Tuesday. Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) rose 11.7 percent to $10.35 in pre-market trading. Ariad Pharmaceuticals disclosed that its Phase 1/2 trial data on investigational drug brigatinib were published in The Lancet Oncology. AK Steel Holding Corporation (NYSE: AKS) rose 11.2 percent to $6.75 in pre-market trading after gaining 3.23 percent on Tuesday. Pretium Resources Inc (NYSE: PVG) rose 11 percent to $10.50 in pre-market trading after declining 1.66 percent on Tuesday. First Majestic Silver Corp (NYSE: AG) rose 9.3 percent to $8.90 in the pre-market trading session. First Majestic reported Q3 earnings of $0.07 per share on revenue of $79.3 million. Silver futures gained 2.2 percent to $18.77 an ounce. Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) rose 9.2 percent to

5 Best Biotech Stocks To Buy For 2017: Medivation Inc.(MDVN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    RBC’s Simos Simeonidis and Matthew Eckler try to find the right comparison for Pfizer’s (PFE) purchase of Medivation (MDVN):

    Scott Eisen/Bloomberg News

    We were obviously wrong with our Sector Perform rating: while we knew an M&A transaction was definitely a good possibility, we just could not get to this level of valuation using a realistic Xtandi model and thus could not recommend the stock. The only way for us to get to $81.50 (or even to $60-$70/share) would have been to assign very significant value to talazoparib. And we could not do that given the amount of available clinical evidence.Medivation shareholders who held on to their shares past the $50′s, did just that, were proven right and are now rewarded for it, since they believed that someone would be willing to pay for this asset just months ahead of Phase III data. The key question is why would a company be willing to part with what they claim/think may be a multibillion dollar drug that works in multiple cancers. We believe the obvious answer is because they’re smart and understand drug development risk better than most. We’ll know in a matter of months whether Pfizer/Medivation is like Amgen (AMGN)-Onyx (carfilzomib) or not.

  • [By Lisa Levin]

    Shares of Medivation Inc (NASDAQ: MDVN) got a boost, shooting up 24 percent to $46.35 amid word of a new report from Bloomberg, saying the company is working with bankers to defend itself against preliminary interest of a takeover. However, Reuters separately reported the company is working with JPMorgan to handle interest from other companies, but said Medivation has no interest in selling itself.

  • [By Ben Levisohn]

    Last night, Bloomberg reported that Sanofi (SNY) had made a bid for Medivation (MDVN) but had been rebuffed, while noting that other companies–perhaps Gilead Sciences (GILD), Amgen (AMGN) or AstraZeneca (AZN)?–were also on the prowl. SunTrust Robinson Humphrey’s Peter Lawson explains why Medivation might be biotech’s most wanted:

5 Best Biotech Stocks To Buy For 2017: Biogen Idec Inc(BIIB)

Advisors’ Opinion:

  • [By Ben Levisohn]

    BMO Capital Markets analyst M. IanSomaiya and team take a look at the “clinical readouts through the end of 2016″ and find upside catalysts for Celgene (CELG), Amgen (AMGN), Biogen (BIIB), and Gilead Sciences (GILD) They explain:

  • [By Ben Levisohn]

    Do we need to remind you how hard biotech stocks have been hit this year? If you read this blog, probably not, but we’ll do it anyway. The iShares Nasdaq Biotechnology ETF (IBB) has fallen 24%, while Gilead Sciences (GILD) has declined 8.7%, Biogen (BIIB) has fallen 17%, Celgene (CELG) has dropped 16%, and Regeneron Pharmaceuticals (REGN) has plunged 32%. Yet despite these drops–and the decline in valuation that accompanied them–the Janus Equity Team contends nothing has changed for the sector:

  • [By Chris Lange]

    Biogen Inc. (NASDAQ: BIIB) had its short interest decrease slightly to 2.36 million shares from the previous 2.55 million. The stock closed Wednesday at $319.86, within a 52-week range of $223.02 to $333.65.

  • [By Ben Levisohn]

    On Tuesday, Baird predicted that Gilead Sciences (GILD) will miss earnings forecasts when it releases its financials on April 28. Barclays’ Geoff Meacham and team, however, foresee an earnings beat from Gilead and Amgen (AMGN) as well, but are more cautious on Biogen (BIIB) and Celgene (CELG). They explain why:

5 Best Biotech Stocks To Buy For 2017: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors’ Opinion:

  • [By Paul Ausick]

    Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) lost about 50% Thursday to post a new 52-week low of $35.31 after closing Wednesday at $70.30. The 52-week high is $110.75. Volume of around 15 million was more than 20 times the daily average of around 640,000 shares traded. The company said today that it is discontinuing a late-stage clinical trial.

  • [By Monica Gerson]

    Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session.

    Caterpillar Inc. (NYSE: CAT) Jan17 77.5 Calls Sweep: 1022 @ ASK $4.45: 1066 traded vs 2466 OI: Earnings 7/28 $75.88 Ref Anacor Pharmaceuticals Inc (NASDAQ: ANAC) Jan17 110 Calls: 500 @ Above Ask! $0.40: 509 traded vs 1860 OI: $99.22 Ref Ctrip.com International, Ltd. (ADR) (NASDAQ: CTRP) Jun16 41.25 Calls Sweep: 577 @ ASK $1.75: 649 traded vs 1927 OI: Earnings 6/15 After Close $40.54 Ref Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Jun16 65.0 Calls Sweep: 749 @ ASK $1.85: 813 traded vs 370 OI: $63.08 Ref WhiteWave Foods Co (NYSE: WWAV) Oct16 50.0 Calls: 600 @ ASK $1.60: 601 traded vs 430 OI: $45.16 Ref

    Posted-In: Unusual Put OptionsNews Options Markets

5 Best Dividend Stocks To Invest In 2017

The ECA Marcellus Trust I (NYSE:ECT) is a 100% natural gas pure play which has a royalty interest in 66 horizontal natural gas wells drilled in the Marcellus Shale formation. All of the wells were developed in the 2010 to 2013 time frame and are currently producing.

The shares of ECT have recently shown signs of a market top in trading, with a high reached in early October being met with stiff resistance and market selling leading up to the recent distribution announcement. Since the distribution announcement of $0.071 per share on November 9th, ECT’s shares recovered strength, and are maintaining value ex-dividend as this report is written.

Click to enlarge

5 Best Dividend Stocks To Invest In 2017: Microchip Technology Incorporated(MCHP)

Advisors’ Opinion:

  • [By Beth Piskora]

    They are listed below:

    Altera (ALTR)yielding 1.7%

    Apple (AAPL)yielding 2.5%

    Applied Materials (AMAT)yielding 2.6%

    Cisco (CSCO)yielding 2.9%

    EMC Corp. (EMC)yielding 1.5%

    International Business Machines (IBM)yielding 2.0%

    KLA-Tencor (KLAC)yielding 3.2%

    Microchip Technology (MCHP)yielding 3.6%

    Oracle (ORCL)yielding 1.5%

    Qualcomm (QCOM)yielding 2.1%

    Texas Instruments (TXN)yielding 2.9%

    Xilinx (XLNX)yielding 2.3%

    Subscribe to S&P’s The Outlook here

5 Best Dividend Stocks To Invest In 2017: Cellcom Israel Ltd.(CEL)

Advisors’ Opinion:

  • [By Monica Gerson]

    Cellcom Israel Ltd. (NYSE: CEL) is estimated to post its earnings for the latest quarter.

    Quotient Ltd (NASDAQ: QTNT) is projected to post a quarterly loss at $0.59 per share on revenue of $4.75 million.

5 Best Dividend Stocks To Invest In 2017: Nucor Corporation(NUE)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Then there are the steel plays. United States Steel Corp. (NYSE: X) was up 7.4% at $27.61 late on Monday. It has a market cap of $4.5 billion. Over the past five trading days the stock has gained 30%. Nucor Corp. (NYSE: NUE) was last seen up 1% at $59.34. Nucor has a total market cap of $18.8 billion. Over the past fivetrading days the stock has gained 17%.

  • [By Wayne Duggan]

    JPMorgan names United States Steel Corporation (NYSE: X), AK Steel Holding Corporation (NYSE: AKS), Steel Dynamics, Inc. (NASDAQ: STLD) and Nucor Corporation (NYSE: NUE) as its top steel stock picks.

  • [By Garrett Baldwin]

    Possible names floated have included two businessmen. First, campaign economic adviser and billionaire Wilbur Ross, or top trade adviser Dan DiMicco, the former CEO of steelmaker Nucor Corp. (NYSE: NUE).

5 Best Dividend Stocks To Invest In 2017: Paychex Inc.(PAYX)

Advisors’ Opinion:

  • [By Monica Gerson]

    Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

    Paychex, Inc. (NASDAQ: PAYX) is estimated to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Paychex shares rose 1.10 percent to close at $56.14 on Wednesday. Wall Street expects Micron Technology, Inc. (NASDAQ: MU) to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. Micron shares rose 0.76 percent to $13.29 in after-hours trading. Pier 1 Imports Inc (NYSE: PIR) reported a wider-than-expected loss for its first quarter and issued a weak outlook. Pier 1 Imports shares dropped 6.07 percent to $5.11 in the after-hours trading session. Analysts are expecting McCormick & Company, Incorporated (NYSE: MKC) to have earned $0.74 per share on revenue of $1.06 billion in the latest quarter. McCormick shares fell 0.59 percent to $102.10 in after-hours trading.

    Posted-In: Stocks To WatchEarnings News Guidance Pre-Market Outlook Markets Trading Ideas

  • [By Monica Gerson]

     

    Darden Restaurants, Inc. (NYSE: DRI) is estimated to report its quarterly earnings at $1.08 per share on revenue of $1.81 billion. ConAgra Foods Inc (NYSE: CAG) is expected to report its quarterly earnings at $0.52 per share on revenue of $2.89 billion. Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.49 per share on revenue of $751.52 million. Micron Technology, Inc. (NASDAQ: MU) is expected to post a quarterly loss at $0.09 per share on revenue of $2.95 billion. McCormick & Company, Incorporated (NYSE: MKC) is estimated to report its quarterly earnings at $0.74 per share on revenue of $1.06 billion. Constellation Brands, Inc. (NYSE: STZ) is expected to report its quarterly earnings at $1.51 per share. Schnitzer Steel Industries, Inc. (NASDAQ: SCHN) is estimated to report its quarterly earnings at $0.18 per share on revenue of $356.41 million. Franklin Covey Co. (NYSE: FC) is expected to post its quarterly earnings at $0.08 per share on revenue of $49.89 million. Lindsay Corporation (NYSE: LNN) is projected to report its quarterly earnings at $0.99 per share on revenue of $148.43 million.

    Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets

  • [By Monica Gerson]

    Paychex, Inc. (NASDAQ: PAYX) is projected to report its quarterly earnings at $0.50 per share on revenue of $751.20 million.

    UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.26 per share on revenue of $362.62 million.

5 Best Dividend Stocks To Invest In 2017: S&P Smallcap 600(PH)

Advisors’ Opinion:

  • [By Charles Mizrahi, President and CEO, Hampton Investors, Inc.]

    Parker Hannifin (PH) generates strong revenue from its aerospace division, while its primary industrial segment is lagging.

    Overall, we like the company’s balanced portfolio. PH had solid order rates this past year with backlog of $3.6 billion between its industrial and aerospace segments.

Top Long Term Stocks To Invest In Right Now

The Q3 2016 earnings report for small cap homebuilder stock KB Home (NYSE: KBH) is scheduled for before the market opens onTuesday (September 20th) with the stock beating expectations the last time around.

A technical chart for small cap KB Home shows shares peaking at the end of July and in a downtrend since then:

A long term performance chart shows KB Home underperforming large cap D.R. Horton, Inc (NYSE: DHI) and mid capsLennar Corporation (NYSE: LEN) and PulteGroup, Inc (NYSE: PHM) with much of the outperformance of homebuilder stocks coming earlier in the recovery with shares moving sideways since then:

Top Long Term Stocks To Invest In Right Now: Genie Energy Ltd.(GNE)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Thursday, utilities shares fell by 0.75 percent. Meanwhile, top losers in the sector included Genie Energy Ltd (NYSE: GNE), down 5 percent, and Consolidated Water Co. Ltd. (NASDAQ: CWCO), down 2 percent.

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares fell by 0.58 percent. Meanwhile, top losers in the sector included Middlesex Water Company (NASDAQ: MSEX), down 2 percent, and Genie Energy Ltd (NYSE: GNE), down 4 percent.

Top Long Term Stocks To Invest In Right Now: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Lisa Levin]

    Novocure Ltd (NASDAQ: NVCR) shares shot up 22 percent to $7.27 after the company posted a narrower-than-expected Q3 loss.

    Shares of TriNet Group Inc (NYSE: TNET) got a boost, shooting up 15 percent to $20.43. TriNet reported Q3 earnings of $0.29 per share on revenue of $770.5 million.

Top Long Term Stocks To Invest In Right Now: Hooker Furniture Corporation(HOFT)

Advisors’ Opinion:

  • [By Monica Gerson]

    Hooker Furniture Corporation (NASDAQ: HOFT) is estimated to report its quarterly earnings at $0.40 per share on revenue of $62.20 million.

    SeaChange International (NASDAQ: SEAC) is projected to post its quarterly earnings at $0.01 per share on revenue of $30.49 million.

Top Long Term Stocks To Invest In Right Now: Discover Financial Services(DFS)

Advisors’ Opinion:

  • [By JACK HOUGH]

    Like CVS, Discover has trounced the broad market over the long term but sold off recently. It’s down more than 15% this year. Costs rose early in the year in part due to one-time expenses related to anti-money-laundering efforts and other regulatory concerns. Analysts predict an offsetting decline in expenses next year. Don’t confuse Discover with a company that’s primarily in the business of running a credit-card network, like Visa (V) and MasterCard (MA). It’s basically a credit-card lender, like Capital One Financial (COF), that runs its own network to gain a competitive advantage.

    By saving on network fees, Discover can offer attractive card rewards, including a popular cash-back program. Any card lender can offer cash back, of course, but being too aggressive risks hurting margins. Discover has grown its portfolio of credit-card loans much faster than big banks have in recent years. And it has done so with industry-leading returns on capital. Rising growth could be on the way. Early this year, Discover went on a marketing spree. Last quarter, it reported its best card growth since 2007. Historically, new-card growth and loan growth have been closely correlated. In a November note to investors, Morgan Stanley analyst Cheryl Pate predicted accelerating loan growth within six months. Meanwhile, defaults remain low. Shares sell for less than 10 times projected earnings for the next four quarters, down from 12 times at the end of last year. They could rise 20% on a combination of earnings growth and a valuation rebound. The dividend yield is 2%. 

  • [By Ben Levisohn]

    Synchrony Financial (SYF) tumbled 13% yesterday after the credit-card issuer said it was seeing more bad loans, an announcement that also rocked Discover Financial Services (DFS), Capital One Financial (COF) and American Express (AXP). Jefferies analyst John Hecht and team call the plunge in Synchrony Financial “an attractive entry point”:

  • [By Spencer White]

    The analyst believes AmEx has a “less competitive edge” in the volume game, and concluded with a warning to avoid the stock. He recommended that investors looking for transaction or card loan exposure should look to Visa Inc (NYSE: V) and Discover Financial Services (NYSE: DFS), respectively.